John P. Sfakianos, MD

Articles by John P. Sfakianos, MD

John Sfakianos, MD, on dual immune checkpoint inhibition in NMIBC

January 29th 2026

John P. Sfakianos, MD, shares the clinical rationale for the phase 2 ENHANCE trial, evaluating the addition of NKG2A inhibition to PD-1/PD-L1 inhibition in NMIBC.

John Sfakianos, MD, on moving immunotherapy earlier in NMIBC treatment pathway

ByJohn P. Sfakianos, MD

January 21st 2026

John P. Sfakianos, MD, outlines the scientific rationale for combining systemic immunotherapy with BCG in the BCG-naïve NMIBC setting.

John P. Sfakianos, MD, on the role of urine-based biomarkers in microhematuria evaluation

ByJohn P. Sfakianos, MD

September 16th 2025

John P. Sfakianos, MD, discusses the significance of urine-based biomarkers for intermediate-risk patients and outlines key findings from the STRATA study.

John P. Sfakianos, MD

Articles by John P. Sfakianos, MD

John Sfakianos, MD, on dual immune checkpoint inhibition in NMIBC

John Sfakianos, MD, on moving immunotherapy earlier in NMIBC treatment pathway

John P. Sfakianos, MD, on the role of urine-based biomarkers in microhematuria evaluation

Latest Updated Articles

Trending on Urology Times

FDA approves sildenafil oral film for men with erectile dysfunction

The UroOnc Minute: Adjuvant Therapy in Renal Cell Carcinoma, with Brian Shuch, MD

Head-to-head analysis shows OS benefit with apalutamide vs darolutamide in mCSPC

URO-1 prostate biopsy devices adopted across Novant Health System as clinical study continues

Pearls & Perspectives: Modern Semen Testing and Male Fertility Care, with Thomas Masterson, MD